论文部分内容阅读
目的分析顺德区无偿献血者核酸检测(NAT)结果,了解顺德地区核酸检测(NAT)呈反应性结果人群分布情况。方法采用美国罗氏全自动NAT检测分析系统,对2015年1月~2016年12月血站经2遍不同厂家ELISA检测及ALT检测,结果均呈非反应性的献血者58 715人份血液标本进行HBV、HCV、HIV 3项NAT联检,对检出有反应性的混样池进行单人份拆分。结果在58 715例2遍不同厂家ELISA检测及ALT检测均呈非反应性的血液标本中,共检测9 786个标本混样池,其中116个混样池呈反应性,混样池阳性率为1.19%(116/9786);对混检呈反应性的混样池所属标本进行拆分单检,呈反应性的标本为69例,拆分阳性反应率为59.48%(69/116)。NAT检测出69例HBV-DNA呈反应性,标本阳性率为0.12%(69/58715),HCV-RNA和HIV-RNA的结果均呈非反应性;在69例HBV-DNA呈反应性的标本中,按男女性别、户籍、献血次数等因素进行分析统计,均具有统计学差异(P<0.05)。结论目前顺德地区血清学ELISA检测合格血液中存在的输血传播疾病风险主要是输血感染HBV;通过进行核酸检测,可以分析掌握HBV、HCV、HIV在本区献血人群中的分布规律,调整有关献血招募策略,有助于进一步提高血液安全。
Objective To analyze the results of nucleic acid detection (NG) in blood donors in Shunde District to find out the distribution of nucleic acid test (NAT) in Shunde District. Methods The Roche automatic NAT detection and analysis system was used in the United States. From January 2015 to December 2016, blood samples from 58 715 blood donors of non-reactive blood donors were tested by two different ELISA tests and ALT tests by different manufacturers. HBV, HCV, HIV 3 NAT joint inspection, detection of reactive mixed pool single split. Results In 58 715 cases of 2 ELISA tests and ALT tests in different factories, non-reactive blood samples were collected. A total of 9 786 specimens were tested, of which 116 were mixed and the positive rate was 1.19% (116/9786). The samples that were re-tested for mixed reactivity were divided into single samples. The number of reactivity samples was 69 and the positive reaction rate was 59.48% (69/116). The positive rate of HBV-DNA in 69 samples was 0.12% (69/58715). The results of HCV-RNA and HIV-RNA were all non-responsive. In 69 samples with HBV-DNA reactive , According to gender and gender, household registration, blood donation times and other factors analysis and statistics, all with statistical differences (P <0.05). Conclusions At present, serological ELISA in Shunde is mainly used to detect transfusion-transmitted HBV infection. The detection of nucleic acid can be used to analyze the distribution of HBV, HCV and HIV in blood donors in this area and to adjust the blood donation Strategy to help further improve blood safety.